These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 33404689)
1. Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial. Ning X; Kuang Y; Yang G; Xie J; Miao D; Guo C; Huang Z Naunyn Schmiedebergs Arch Pharmacol; 2021 Jun; 394(6):1275-1283. PubMed ID: 33404689 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial. Marcatto LR; Sacilotto L; Bueno CT; Facin M; Strunz CM; Darrieux FC; Scanavacca MI; Krieger JE; Pereira AC; Santos PC BMC Cardiovasc Disord; 2016 Nov; 16(1):224. PubMed ID: 27855643 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Wallentin L; Yusuf S; Ezekowitz MD; Alings M; Flather M; Franzosi MG; Pais P; Dans A; Eikelboom J; Oldgren J; Pogue J; Reilly PA; Yang S; Connolly SJ; Lancet; 2010 Sep; 376(9745):975-83. PubMed ID: 20801496 [TBL] [Abstract][Full Text] [Related]
4. Effect of medication timing on anticoagulation stability in users of warfarin (the INRange RCT): study protocol for a randomized controlled trial. Heran BS; Allan GM; Green L; Korownyk C; Kolber M; Olivier N; Flesher M; Garrison S Trials; 2016 Aug; 17(1):391. PubMed ID: 27488365 [TBL] [Abstract][Full Text] [Related]
5. Dosing options for decreasing the time to achieve therapeutic anticoagulation when reinitiating warfarin: a case series. Schultz KT; Bungard TJ Pharmacotherapy; 2011 Aug; 31(8):793-805. PubMed ID: 21923606 [TBL] [Abstract][Full Text] [Related]
6. Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. Gage BF; Bass AR; Lin H; Woller SC; Stevens SM; Al-Hammadi N; Anderson JL; Li J; Rodriguez T; Miller JP; McMillin GA; Pendleton RC; Jaffer AK; King CR; Whipple B; Porche-Sorbet R; Napoli L; Merritt K; Thompson AM; Hyun G; Hollomon W; Barrack RL; Nunley RM; Moskowitz G; Dávila-Román V; Eby CS JAMA; 2019 Sep; 322(9):834-842. PubMed ID: 31479138 [TBL] [Abstract][Full Text] [Related]
7. Association between apolipoprotein E genotype and warfarin response during initial anticoagulation. He S; Zhang H; Cao Y; Nian F; Chen H; Chen W; Auchoybur ML; Yin L; Tao Z; Tang S; Chen X Biomed Pharmacother; 2018 May; 101():251-256. PubMed ID: 29494962 [TBL] [Abstract][Full Text] [Related]
8. Randomized, placebo-controlled trial of orally administered vitamin K1 for warfarin-associated coagulopathy in Chinese patients with mechanical heart valves. Zhang H; Li M; Ao XL; Dong YJ; Dong L Eur J Clin Pharmacol; 2021 Sep; 77(9):1333-1339. PubMed ID: 33783553 [TBL] [Abstract][Full Text] [Related]
9. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766 [TBL] [Abstract][Full Text] [Related]
10. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708 [TBL] [Abstract][Full Text] [Related]
11. Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study. Genovesi S; Rebora P; Gallieni M; Stella A; Badiali F; Conte F; Pasquali S; Bertoli S; Ondei P; Bonforte G; Pozzi C; Rossi E; Valsecchi MG; Santoro A J Nephrol; 2017 Aug; 30(4):573-581. PubMed ID: 27834042 [TBL] [Abstract][Full Text] [Related]
12. Genotype-Guided Dosing of Warfarin in Chinese Adults: A Multicenter Randomized Clinical Trial. Guo C; Kuang Y; Zhou H; Yuan H; Pei Q; Li J; Jiang W; Ng CM; Chen X; Huo Y; Cui Y; Wang X; Yu J; Sun X; Yu W; Chen P; Miao D; Liu W; Yu Z; Ouyang Z; Shi X; Lv C; Peng Z; Xiong G; Zeng G; Zeng J; Dai H; Peng J; Zhang Y; Xu F; Wu J; Chen X; Gong H; Yang Z; Wu X; Fang Q; Yang L; Li H; Tan H; Huang Z; Tang X; Yang Q; Tu S; Wang X; Xiang Y; Huang J; Wang X; Cai J; Jiang S; Huang L; Peng J; Gong L; Zou C; Yang G Circ Genom Precis Med; 2020 Aug; 13(4):e002602. PubMed ID: 32510984 [TBL] [Abstract][Full Text] [Related]
13. Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil. Freitas CG; Walsh M; Atallah ÁN BMC Cardiovasc Disord; 2017 Jun; 17(1):148. PubMed ID: 28592234 [TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of genotype-guided warfarin anticoagulation in Chinese elderly patients with nonvalvular atrial fibrillation. Zhu Y; Xu C; Liu J J Clin Pharm Ther; 2020 Dec; 45(6):1466-1473. PubMed ID: 32710457 [TBL] [Abstract][Full Text] [Related]
15. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Schulman S; Parpia S; Stewart C; Rudd-Scott L; Julian JA; Levine M Ann Intern Med; 2011 Nov; 155(10):653-9, W201-3. PubMed ID: 22084331 [TBL] [Abstract][Full Text] [Related]
16. The efficacy of 3-mg warfarin initiating dose in adult Thai patients, who required long-term anticoagulant therapy. Suwanawiboon B; Kongtim P; Chinthammitr Y; Ruchutrakool T; Wanachiwanawin W J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S225-31. PubMed ID: 21721451 [TBL] [Abstract][Full Text] [Related]
17. Comparison of warfarin dosage fluctuation with time in therapeutic range for bleeding or thromboembolism rate in Chinese patients. Yu HY; Tsai HE; Chen YS; Hung KY J Formos Med Assoc; 2019 Feb; 118(2):611-618. PubMed ID: 30126761 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials. Shi C; Yan W; Wang G; Wang F; Li Q; Lin N PLoS One; 2015; 10(12):e0144511. PubMed ID: 26672604 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Hori M; Matsumoto M; Tanahashi N; Momomura S; Uchiyama S; Goto S; Izumi T; Koretsune Y; Kajikawa M; Kato M; Ueda H; Iwamoto K; Tajiri M; Circ J; 2013; 77(3):632-8. PubMed ID: 23229461 [TBL] [Abstract][Full Text] [Related]
20. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA; J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]